Protocol for fever control using external cooling in mechanically ventilated patients with septic shock: SEPSISCOOL II randomised controlled trial

Armelle Guénégou-Arnoux,Juliette Murris,Stéphane Bechet,Camille Jung,Johann Auchabie,Julien Dupeyrat,Nadia Anguel,Pierre Asfar,Julio Badie,Dorothée Carpentier,Benjamin Chousterman,Jeremy Bourenne,Agathe Delbove,Jérôme Devaquet,Nicolas Deye,Guillaume Dumas,Anne-Florence Dureau,Jean-Baptiste Lascarrou,Stephane Legriel,Christophe Guitton,Caroline Jannière-Nartey,Jean-Pierre Quenot,Jean-Claude Lacherade,Julien Maizel,Armand Mekontso Dessap,Bruno Mourvillier,Philippe Petua,Gaetan Plantefeve,Jean-Christophe Richard,Alexandre Robert,Clément Saccheri,Ly Van Phach Vong,Sandrine Katsahian,Frédérique Schortgen
DOI: https://doi.org/10.1136/bmjopen-2022-069430
IF: 3.006
2024-01-30
BMJ Open
Abstract:Introduction Fever treatment is commonly applied in patients with sepsis but its impact on survival remains undetermined. Patients with respiratory and haemodynamic failure are at the highest risk for not tolerating the metabolic cost of fever. However, fever can help to control infection. Treating fever with paracetamol has been shown to be less effective than cooling. In the SEPSISCOOL pilot study, active fever control by external cooling improved organ failure recovery and early survival. The main objective of this confirmatory trial is to assess whether fever control at normothermia can improve the evolution of organ failure and mortality at day 60 of febrile patients with septic shock. This study will compare two strategies within the first 48 hours of septic shock: treatment of fever with cooling or no treatment of fever. Methods and analysis SEPSISCOOL II is a pragmatic, investigator-initiated, adaptive, multicentre, open-label, randomised controlled, superiority trial in patients admitted to the intensive care unit with febrile septic shock. After stratification based on the acute respiratory distress syndrome status, patients will be randomised between two arms: (1) cooling and (2) no cooling. The primary endpoint is mortality at day 60 after randomisation. The secondary endpoints include the evolution of organ failure, early mortality and tolerance. The target sample size is 820 patients. Ethics and dissemination The study is funded by the French health ministry and was approved by the ethics committee CPP Nord Ouest II (Amiens, France). The results will be submitted for publication in peer-reviewed journals. Trial registration number NCT04494074.
medicine, general & internal
What problem does this paper attempt to address?
### Problems the Paper Aims to Solve This paper aims to evaluate whether the use of external cooling to control body temperature in patients with febrile septic shock in the Intensive Care Unit (ICU) can improve organ function recovery and reduce 60-day mortality. #### Main Research Question: - **Research Hypothesis**: Compared to no fever treatment, maintaining febrile patients at normal body temperature (36.5°C–37°C) using external cooling can significantly reduce 60-day mortality after randomization. #### Secondary Research Questions: - Changes in organ function: Assessed by the number of organ support-free days by day 28 and changes in the Sequential Organ Failure Assessment (SOFA) score. - Incidence of acute kidney injury (AKI): Based on the Kidney Disease: Improving Global Outcomes (KDIGO) criteria and the initiation of renal replacement therapy (RRT). - Incidence of acquired acute respiratory distress syndrome (ARDS) after randomization. - 28-day mortality after randomization. - Incidence of hospital-acquired infections within 28 days after randomization. - Tolerability of the two strategies: Including the incidence of shivering, seizures, hypothermia, and arrhythmias. ### Study Design - **Trial Type**: Multicenter, open-label, randomized controlled superiority trial. - **Sample Size**: Planned to recruit 820 patients. - **Randomization**: Stratified by the presence of ARDS and using adaptive randomization to ensure balance between groups. - **Primary Endpoint**: 60-day mortality after randomization. - **Secondary Endpoints**: Changes in organ function, early mortality, and incidence of adverse events.